| 1 |
ION363 (ulefnersen) |
3
|
- antisense oligonucleotide treatment for people carrying a mutation in FUS gene
- recruiting in CA, MD, MA, MO, NY, OH, UT
|
IONIS
|
|
2
|
Masitinib |
3
|
- 33% chance of placebo
- trial volunteers will be separated into 3 groups, a high dose with riluzole, a low dose with riluzole, or placebo with riluzole
- recruiting in AL, CA, KY, MD, MA, VA
|
AB Sciences
|
|
3 |
Tofersen - ATLAS (for presymptomatic SOD1) |
3
|
- biomarkers will be monitored over time and tofersen or placebo will be administered if specific biomarker changes occur
- antisense oligonucleotide treatment for people carrying specific SOD1 mutations, but no current symptoms of ALS
- recruiting in AZ, CA, FL, GA, IL, MD, MA, MO, NY, TX
|
Biogen
|
|
4 |
Ibudilast |
2/3
|
- 50% chance of placebo for 12 months followed by an open label extension for 6 months
- recruiting in CA, FL, GA, IN, KS, MD, MN, NY, NC, OR, PA, VA
|
MediciNova
|
5 | Rapa-501 | 2/3 | - no placebo
-
autologous T cells are administered intravenously for 6 months followed by an additional 6 months of observation
- recruiting in MA, NJ
| Rapa Therapeutics |
|
6 |
AP-101 |
2
|
- placebo-controlled trial
- drug is delivered intravenously
- trial is for people carrying SOD1 mutation or sporadic ALS
- recruiting in CA
|
AL-S Pharma
|
|
7 |
Vitamin E, N-acetyl cysteine, L-cystine, nicotinamide, and taurursodiol |
2
|
-
no placebo
- recruiting in TX
|
Dallas VA Medical Center
|
|
8 |
Istradefylline and AIH |
1/2
|
-
crossover study: all trial volunteers will receive placebo and all trial volunteers will receive active treatment at different timepoints
- recruiting in FL
|
University of Florida
|
|
9 |
baricitinib |
1
|
-
no placebo
- includes people living with different neurodegenerative diseases including ALS
- recruiting in MA
|
Massachusetts General Hospital
|
10 | | 1 | - placebo controlled trial
- umbilical cord derived T regulatory cells delivered intravenously
- recruiting in NY, TX
| Cellenkos |
|
11 |
CNS10-NPC-GDNF |
1
|
-
no placebo
- cells that produce GDNF (a growth factor) will be transplanted into motor cortex of brain
- recruiting in CA
|
Cedars-Sinai Medical Center
|
| 12 | CNM-Au8 | EAP | - Expanded Access Program for people that are not eligible for trials
- CNM-Au8 will be administered for up to 96 weeks orally or by feeding tube
- sites in AZ, CA, CT, FL, IL, KS, MI, NE, NC, OR, PA, TX,
| Clene Nanomedicine |
| 13 | Rapa 501 | EAP | - Expanded Access Program for people that are not eligible for trials
- Autologous hybrid TREG/Th2 cells delivered intravenously
- sites in MA, NJ
| Rapa Therapeutics
|
| 14 | Pridopidine | EAP | - Expanded Access Program for people that are not eligible for trials
- pridopidine will be administered twice daily by mouth or feeding tube for 2 years
- sites not yet listed, but contact information is available on clinicaltrials.gov
| Prilenia |